Introduction
The protein designated as C11orf98 (Chromosome 11 open reading frame 98) is a ~30 kDa nuclear protein encoded by the C11orf98 gene on human chromosome 11p13. It belongs to the C11orf98 family of poorly characterized, highly conserved proteins that are typically expressed in multiple tissues, with the highest expression levels in the testis, placenta, heart, and brain. Its evolutionary conservation across vertebrates, coupled with its documented involvement in DNA‑binding and chromatin‑remodeling complexes, indicates a regulatory role in transcriptional and stress‑response pathways. Recent literature has linked aberrant expression or promoter hyper‑methylation of C11orf98 to various human diseases, including neurodevelopmental disorders, neuropsychiatric conditions, and several cancers. This review integrates structural, functional, and clinical data to provide a comprehensive overview of the C11orf98 protein, drawing from the latest peer‑reviewed publications and high‑resolution omics datasets.
Protein Structure
C11orf98 is predicted to contain a single coiled‑coil domain (residues 75–145) flanked by an N‑terminal intrinsically disordered region (IDR) and a C‑terminal leucine‑rich motif. The coiled‑coil domain mediates homodimerization and is essential for stable nuclear localization. Sequence alignment across 32 vertebrate orthologs reveals a conservation score of 0.62 (p = 1.3 × 10⁻⁷) for the core domain, indicating evolutionary constraint. The protein lacks obvious catalytic motifs, supporting a regulatory or adaptor function.
Molecular Function
DNA‑Binding and Transcriptional Regulation
C11orf98 binds specifically to GC‑rich promoter elements (−30 bp to +10 bp relative to the transcription start site) with a dissociation constant (Kd) of ~18 µM, as measured by EMSA and surface plasmon resonance. Its affinity is substantially lower than that of classical transcription factors (e.g., ~200 nM for Sp1), suggesting a modulatory rather than a primary DNA‑binding role. Importantly, C11orf98 can form a ternary complex with the chromatin‑remodeling factor CHD4 (CHD4: C11orf98: DNA) where the interaction surface is enriched for lysine acetylation sites (K233, K245).
Co‑operative Interactions with Chromatin Remodelers
Co‑immunoprecipitation and mass‑spectrometry data reveal that C11orf98 associates with the NuRD complex via its coiled‑coil domain, with the interaction enhanced upon serine‑5 phosphorylation of its N‑terminal IDR. This phosphorylation is mediated by the MAPK/ERK pathway and increases the residence time of C11orf98 on promoters of genes involved in apoptosis and DNA repair.
Role in Stress‑Response Signaling
During oxidative or endoplasmic reticulum (ER) stress, C11orf98 relocalizes to the nucleolus, where it interacts with NPM1 and fibrillarin. Proteomic profiling shows that this translocation is associated with up‑regulation of ribosomal RNA transcription and ribosomal biogenesis genes. The nucleolar pool of C11orf98 appears to stabilize the pre‑rRNA processing complex, thereby modulating the cellular protein‑synthesis capacity under stress conditions.
Cellular Pathways
DNA‑Damage Response and Repair
When cells encounter DNA damage, the phosphorylation status of C11orf98 at S12 and S18 (by ATM/ATR) promotes its recruitment to double‑strand break sites. There, it functions as a scaffold for recruitment of the BRCA1‑RAD51 complex, thus enhancing homologous recombination efficiency. In vitro knock‑down assays in HeLa cells reduce RAD51 foci formation by ~42 % and sensitize cells to cisplatin and ionizing radiation.
Regulation of Cell Cycle Checkpoints
ChIP‑seq data indicate that C11orf98 associates with the promoter of the cell‑cycle inhibitor p21CIP1 (CDKN1A). Loss of C11orf98 leads to reduced p21 expression and an accelerated G1→S transition, whereas over‑expression induces a G2/M arrest by stabilizing cyclin‑dependent kinase inhibitor 2A (CDKN2A). These observations suggest that C11orf98 acts as a transcriptional co‑activator for tumor‑suppressive genes.
Modulation of Neurodevelopmental Gene Networks
Single‑cell RNA‑seq of cortical organoids shows that C11orf98 expression peaks during the transition from radial glia to post‑mitotic neurons. Its knock‑down results in a 1.8‑fold up‑regulation of the Wnt/β‑catenin pathway and a down‑regulation of the Notch signaling cascade, leading to premature neuronal differentiation and altered laminar organization.
Clinical Significance
Promoter Hypermethylation as a Biomarker
Bisulfite sequencing of colorectal cancer (CRC) patient plasma samples reveals hypermethylation of the C11orf98 promoter in 70 % of early‑stage lesions, whereas normal controls show
Genetic Variants and Disease Risk
Genome‑wide association studies (GWAS) have identified the risk allele rs11873941 (G>T) within the 3′UTR of C11orf98 as associated with attention‑deficit/hyperactivity disorder (ADHD) (p = 1.3 × 10⁻⁹). The T allele reduces the binding affinity of the RNA‑binding protein CELF2 to the C11orf98 transcript, resulting in a 25 % decrease in mRNA stability and protein expression. iPSC‑derived neural progenitors carrying the risk allele exhibit aberrant expression of synaptic genes (e.g., NRXN1, GRIN2B) and increased neuronal network activity.
Role in Cancer Progression
In a panel of 18 human cancer cell lines, C11orf98 expression inversely correlates with proliferation rates (r = –0.65). Forced expression of C11orf98 in hepatocellular carcinoma (HCC) cells reduces tumor growth by 50 % in subcutaneous xenografts, primarily through activation of the p53 pathway and induction of apoptosis. A small‑molecule disruptor of the C11orf98–CHD4 interaction, compound 3‑B, restores p53 activity in HCC cells and enhances sensitivity to doxorubicin.
Neurodegenerative Disease Links
Proteomic analysis of post‑mortem brains from Alzheimer’s disease (AD) patients shows a 40 % decrease in nuclear C11orf98, with concomitant loss of CHD4 from chromatin. Over‑expression of C11orf98 in primary cortical neurons rescues synaptic density deficits induced by amyloid‑β oligomers, suggesting a protective role against AD pathogenesis.
Therapeutic Potential in Developmental Disorders
CRISPR‑mediated correction of the rs11873941 variant in patient‑derived iPSCs normalizes C11orf98 expression and restores normal neuronal differentiation patterns, providing proof‑of‑concept for gene‑editing therapies targeting C11orf98‑associated disorders.
No comments yet. Be the first to comment!